A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent
activity in previously treated advanced breast cancer. This trial will test combined VEGF
inhibition with sorafenib and bevacizumab in less heavily pre-treated patients with advanced
breast cancer.